Biotherapeutics company Momotaro-Gene has announced the beginning of a Phase 2 clinical trial on their innovative treatment for malignant mesothelioma. The study will analyze the efficacy of the company’s novel gene therapy called MTG201 combined with the PD-1 inhibitor nivolumab (Opdivo) on patients whose cancer has returned. Treatment being tested on patients who have relapsed…
The post Phase 2 Study of Novel Gene Therapy for Mesothelioma Begins at Baylor appeared first on Mesothelioma.net.
from Mesothelioma.net https://ift.tt/2ZVWKfX
via IFTTT
Phase 2 Study of Novel Gene Therapy for Mesothelioma Begins at Baylor
![Phase 2 Study of Novel Gene Therapy for Mesothelioma Begins at Baylor]()
Reviewed by Unknown
on
September 13, 2019
Rating:
No comments: